Business
Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months
OSR Holdings, Inc. (NASDAQ: OSRH) today provided an update regarding the previously announced non-binding term sheet between its subsidiary, Vaximm AG, and BCM Europe AG ("BCME"). The parties have agreed to shorten the exclusivity period from six months to three months, reflecting the strong alignment and confidence between Vaximm and BCME in advancing a definitive exclusive global licensing agreement for VXM01, Vaximm's first-in-class orally administered cancer immunotherapy platform.
About this update from Osr Holdings, Inc.
[{"type":"text","content":"BELLEVUE, Wash., Dec. 2, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today provided an update regarding the previously announced non-binding term sheet between its subsidiary, Vaximm AG, and BCM Europe AG ("BCME"). The parties have agreed to shorten the exclusivity period from six months to three months, reflecting the strong alignment and confidence between Vaximm and BCME in advancing a definitive exclusive global licensing agreement for VXM01, Vaximm's first-in-class orally administered cancer immunotherapy platform.","length":550,"tagName":"p"},{"type":"image","alt":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","displaySize":"","headline":null,"caption":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","className":"","disableSlideshowImg":false,"size":{"original":{"width":334,"height":277,"url":"https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cTh6l6BCVhUkYFTe3KonaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702","width":334,"height":277}},"href":"https://mma.prnewswire.com/media/2393302/OSR_Holdings_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the updated timeline, Vaximm and BCME now expect to negotiate and finalize a definitive agreement within three months, supported by BCME's demonstrated ability to rapidly organize the financing and partnering infrastructure required for a potential global out-license to a major pharmaceutical company, as well as its capacity to expedite and streamline the due-diligence processes.","length":392,"tagName":"p"},{"type":"text","content":"The contemplated financial terms remain unchanged and include:","length":62,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A $20 million upfront payment to Vaximm;","length":40,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to $815 million in clinical, regulatory, and commercial milestone payments; and","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"A pass-through of commercial royalties BCME may receive from future pharmaceutical partners, following milestone differential recovery under a defined delta-recovery mechanism.","length":176,"tagName":"p"}]}],"tagName":"ul","bulletedList":tr...